AR076305A1 - Composiciones de capsulas biodisponibles de compuesto alfa-(n-sulfonamido) acetamida amorfo - Google Patents
Composiciones de capsulas biodisponibles de compuesto alfa-(n-sulfonamido) acetamida amorfoInfo
- Publication number
- AR076305A1 AR076305A1 ARP100101257A ARP100101257A AR076305A1 AR 076305 A1 AR076305 A1 AR 076305A1 AR P100101257 A ARP100101257 A AR P100101257A AR P100101257 A ARP100101257 A AR P100101257A AR 076305 A1 AR076305 A1 AR 076305A1
- Authority
- AR
- Argentina
- Prior art keywords
- peg
- pvp
- capsule
- polyethylene glycol
- pharmaceutical
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002131 composite material Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 9
- 229920001223 polyethylene glycol Polymers 0.000 abstract 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 229920001531 copovidone Polymers 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 3
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 abstract 2
- 229930003427 Vitamin E Natural products 0.000 abstract 2
- 238000002425 crystallisation Methods 0.000 abstract 2
- 230000008025 crystallization Effects 0.000 abstract 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 2
- 239000007903 gelatin capsule Substances 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 229920002689 polyvinyl acetate Polymers 0.000 abstract 2
- 239000011118 polyvinyl acetate Substances 0.000 abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 2
- 229940046009 vitamin E Drugs 0.000 abstract 2
- 235000019165 vitamin E Nutrition 0.000 abstract 2
- 239000011709 vitamin E Substances 0.000 abstract 2
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 abstract 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16906109P | 2009-04-14 | 2009-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076305A1 true AR076305A1 (es) | 2011-06-01 |
Family
ID=42235859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101257A AR076305A1 (es) | 2009-04-14 | 2010-04-14 | Composiciones de capsulas biodisponibles de compuesto alfa-(n-sulfonamido) acetamida amorfo |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8252821B2 (enExample) |
| EP (1) | EP2419090B1 (enExample) |
| JP (1) | JP2012524092A (enExample) |
| KR (1) | KR20120022766A (enExample) |
| CN (1) | CN102395361A (enExample) |
| AR (1) | AR076305A1 (enExample) |
| AU (1) | AU2010236602A1 (enExample) |
| BR (1) | BRPI1015483A2 (enExample) |
| CA (1) | CA2758847A1 (enExample) |
| EA (1) | EA201101286A1 (enExample) |
| MX (1) | MX2011010514A (enExample) |
| NZ (1) | NZ595335A (enExample) |
| TW (1) | TW201041609A (enExample) |
| WO (1) | WO2010120755A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1465861T3 (da) | 2001-12-20 | 2009-08-31 | Bristol Myers Squibb Co | Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere |
| US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| CN102577156B (zh) | 2009-10-02 | 2016-01-20 | Lg电子株式会社 | 用于下行链路参考信号的发送方法和装置 |
| CN103402543B (zh) * | 2010-12-16 | 2015-09-16 | 德克萨斯州立大学董事会 | 用于胃肠外施用的吡咯药物制剂及其制备方法和治疗对吡咯化合物敏感的疾病的使用方法 |
| AU2012250050B2 (en) | 2011-04-28 | 2017-04-06 | Platform Brightworks Two, Ltd. | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
| US20130302414A1 (en) * | 2012-05-07 | 2013-11-14 | Bristol-Myers Squibb Company | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| EP3927324A1 (en) * | 2019-02-22 | 2021-12-29 | Janssen Pharmaceutica NV | Pharmaceutical formulations |
| US12404260B2 (en) | 2019-04-11 | 2025-09-02 | Janssen Pharmaceutica Nv | Pyridine rings containing derivatives as MALT1 inhibitors |
| EP4199911A1 (en) * | 2020-08-21 | 2023-06-28 | JANSSEN Pharmaceutica NV | Pharmaceutical formulations comprising a malt1 inhibitor and a mixture of polyethylene glycol with a fatty acid |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5274094A (en) * | 1990-08-15 | 1993-12-28 | British Bio-Technology Limited | Production of heterobicyclic containing benzene sulfonamides |
| GB9202791D0 (en) * | 1992-02-11 | 1992-03-25 | British Bio Technology | Compounds |
| SK282833B6 (sk) * | 1995-11-17 | 2002-12-03 | Warner-Lambert Company | Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory |
| BR9710752A (pt) | 1996-07-22 | 1999-08-17 | Monsanto Co | Inbidores de metaloprotease de sulfonamida de tiol |
| JP2001523221A (ja) * | 1996-09-01 | 2001-11-20 | ファーモス コーポレイション | 親油性物質の促進された生物学的利用能のための固形共沈物 |
| JPH11343279A (ja) | 1998-03-16 | 1999-12-14 | Shionogi & Co Ltd | スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤 |
| ATE280152T1 (de) | 1999-01-27 | 2004-11-15 | Wyeth Corp | Acetylenische sulfonamid-thiol-tace-inhibitoren |
| US6313123B1 (en) * | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| CN1348442A (zh) | 1999-02-26 | 2002-05-08 | 默克公司 | 新的磺胺化合物及其应用 |
| EP1435910B9 (en) * | 2001-10-19 | 2010-02-03 | Isotechnika Inc. | Novel cyclosporin analog microemulsion preconcentrates |
| DK1465861T3 (da) | 2001-12-20 | 2009-08-31 | Bristol Myers Squibb Co | Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere |
| AU2004230844B2 (en) * | 2003-03-31 | 2010-12-09 | Wyeth | Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof |
| EP1680406A1 (en) | 2003-10-29 | 2006-07-19 | Elan Pharmaceuticals, Inc. | N-substituted benzene sulfonamides |
| US7163942B2 (en) | 2004-04-01 | 2007-01-16 | Pfizer Inc. | Sulfonamide compounds for the treatment of neurodegenerative disorders |
| AU2005237580B2 (en) * | 2004-04-28 | 2011-06-16 | Procarrier, Inc. | Oral formulation for delivery of poorly absorbed drugs |
| RU2378258C2 (ru) | 2004-07-13 | 2010-01-10 | Ф. Хоффманн-Ля Рош Аг | Производные сульфонамида |
| US7144894B2 (en) | 2004-09-23 | 2006-12-05 | Bristol-Myers Squibb Company | Sulfonamide bicyclic compounds |
| BRPI0519036A2 (pt) * | 2004-12-14 | 2008-12-23 | Wyeth Corp | mÉtodo para o tratamento de um paciente acometido por uma doenÇa neuro-degenerativa; composiÇço farmacÊutica para tratar uma doenÇa neuro-degenerativa; e uso de um agonista 5-ht6 ou de um agonista 5-ht6 |
| CA2641013A1 (en) * | 2006-02-17 | 2007-08-30 | Wyeth | Methods for preparing sulfonamide substituted alcohols and intermediates thereof |
| RU2008131051A (ru) * | 2006-02-17 | 2010-03-27 | Вайет (Us) | Избирательное n-сульфонилирование 2-амино трифторалкильнзамещенных спиртов |
| WO2007103683A2 (en) * | 2006-03-01 | 2007-09-13 | Roskamp Research Llc | Compounds for inhibiting beta-amyloid production |
| US8633179B2 (en) | 2007-03-13 | 2014-01-21 | The Trustees Of Columbia University In The City Of New York | Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids |
| WO2009005688A2 (en) | 2007-06-29 | 2009-01-08 | Trustees Of Columbia University In The City Of New York | Activating mutations in notch-1 |
| US8084477B2 (en) * | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| US20110059940A1 (en) | 2008-05-08 | 2011-03-10 | Bristol- Myers Squibb Company | 2-Aryl Glycinamide Derivatives |
| JP2012520875A (ja) | 2009-03-19 | 2012-09-10 | ブリストル−マイヤーズ スクイブ カンパニー | ベータアミロイドペプチド産生阻害剤としての新規アルファ−（ｎ−スルホンアミド）アセトアミド化合物 |
| US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| US20110071199A1 (en) | 2009-03-20 | 2011-03-24 | Bristol-Myers Squibb Company | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease |
| TW201043269A (en) | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
-
2010
- 2010-04-12 US US12/758,385 patent/US8252821B2/en not_active Expired - Fee Related
- 2010-04-13 EA EA201101286A patent/EA201101286A1/ru unknown
- 2010-04-13 EP EP10714418A patent/EP2419090B1/en not_active Not-in-force
- 2010-04-13 AU AU2010236602A patent/AU2010236602A1/en not_active Abandoned
- 2010-04-13 BR BRPI1015483A patent/BRPI1015483A2/pt not_active IP Right Cessation
- 2010-04-13 JP JP2012506123A patent/JP2012524092A/ja active Pending
- 2010-04-13 CA CA2758847A patent/CA2758847A1/en not_active Abandoned
- 2010-04-13 KR KR1020117024036A patent/KR20120022766A/ko not_active Withdrawn
- 2010-04-13 MX MX2011010514A patent/MX2011010514A/es active IP Right Grant
- 2010-04-13 WO PCT/US2010/030862 patent/WO2010120755A1/en not_active Ceased
- 2010-04-13 CN CN2010800164919A patent/CN102395361A/zh active Pending
- 2010-04-13 NZ NZ595335A patent/NZ595335A/xx not_active IP Right Cessation
- 2010-04-14 AR ARP100101257A patent/AR076305A1/es not_active Application Discontinuation
- 2010-04-14 TW TW099111671A patent/TW201041609A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ595335A (en) | 2013-03-28 |
| AU2010236602A1 (en) | 2011-10-13 |
| BRPI1015483A2 (pt) | 2016-04-26 |
| KR20120022766A (ko) | 2012-03-12 |
| MX2011010514A (es) | 2011-11-29 |
| EA201101286A1 (ru) | 2012-04-30 |
| CA2758847A1 (en) | 2010-10-21 |
| US8252821B2 (en) | 2012-08-28 |
| US20100260837A1 (en) | 2010-10-14 |
| CN102395361A (zh) | 2012-03-28 |
| JP2012524092A (ja) | 2012-10-11 |
| WO2010120755A1 (en) | 2010-10-21 |
| EP2419090B1 (en) | 2013-02-13 |
| TW201041609A (en) | 2010-12-01 |
| EP2419090A1 (en) | 2012-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201101286A1 (ru) | Композиции биодоступных капсул некристаллического соединения альфа-(n-сульфонамидо)ацетамина | |
| ES2608818T3 (es) | Métodos y formulaciones para convertir fármacos intravenosos e inyectables en formas de dosificación orales | |
| AR072842A1 (es) | Composicion farmaceutica estabilizada que comprende un ingrediente farmaceuticamente activo no peptidico | |
| EA201200096A1 (ru) | Фармацевтическая композиция ингибитора протеазы вируса гепатита c | |
| DOP2013000085A (es) | Formulacion de capsula | |
| AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
| AR032524A1 (es) | Composicion farmaceutica para capsulas moldeadas; composicion farmaceutica para envueltas de capsulas moldeadas; envuelta, elemento de union o separador de capsula moldeados por inyeccion con las mismas; forma de dosificacion farmaceutica de varios componentes y conjunto de formas de dosificacion de | |
| NZ581589A (en) | Solubilized sterile injectable formulation of docetaxel without Tween 80 | |
| AR038527A1 (es) | Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo | |
| AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
| PE20060003A1 (es) | Formulacion farmaceutica polimerica para moldear por inyeccion | |
| EA200801926A1 (ru) | Таблетки парацетамола с быстрым высвобождением | |
| AR010634A1 (es) | Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv | |
| PE20091949A1 (es) | Formulacion farmaceutica solida con liberacion retardada | |
| AR063538A1 (es) | Tratamiento de la enfermedad de parkinson | |
| CL2007002000A1 (es) | Preparacion farmaceutica para la administracion oral con liberacion controlada de ingrediente activo en el intestino delgado que comprende portadores inertes, ingredientes activo, una capa interna compuesta de 2 capas de difusion para controlar la liberacion y una capa gastrorresistente; metodo de preparacion. | |
| EA201100430A1 (ru) | Стабильная комбинированная фармацевтическая композиция | |
| BR112015010271A8 (pt) | produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos | |
| ES2531241T3 (es) | Composición farmacéutica líquida estable a base de trazodona | |
| AR060869A1 (es) | Composicion farmaceutica solida de gabapentina | |
| CO7170181A2 (es) | Nueva composición de alfentanilo para el tratamiento del dolor agudo | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| AR067450A1 (es) | Composicion faramaceutica que comprende la combinacion de una triazolobenzodiazepina y un agente inhibidor selectivo de la recaptura de serotonina | |
| AR075988A1 (es) | Compuesto de piridiloxi - pirrolidina inhibidor de recaptacion de serotonina y norepinefrina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de dolor cronico | |
| AR051654A1 (es) | Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |